anastrozole / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 0 Diseases   123 Trials   123 Trials   2738 News 


«12345678910111213...4142»
  • ||||||||||  anastrozole / Generic mfg.
    Journal:  The effect of prolonged neoadjuvant endocrine therapy on the efficacy of treatment with breast cancer. (Pubmed Central) -  Dec 4, 2023   
    (2) The expression state of ER or PR may be used as a factor influencing the efficacy of treatment with breast cancer after prolonged treatment. (3) There was no significant effect on the patients' axillary lymph node status and the Ki67 expression before treatment on the clinical efficacy after prolonged treatment.
  • ||||||||||  letrozole / Generic mfg., anastrozole / Generic mfg., tamoxifen / Generic mfg.
    Journal:  Chemical Application of Topological Indices in Infertility Treatment Drugs and QSPR Analysis. (Pubmed Central) -  Dec 4, 2023   
    We compute the topological descriptors with the limiting behaviors associated with these pharmaceutical drugs and offer degree-based topological parameters for them. We conducted a QSPR investigation on the prospective degree-based topological descriptors using quadratic, cubic, exponential, and logarithmic regression models.
  • ||||||||||  anastrozole / Generic mfg.
    Trial primary completion date:  A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS) (clinicaltrials.gov) -  Nov 29, 2023   
    P=N/A,  N=1046, Active, not recruiting, 
    We conducted a QSPR investigation on the prospective degree-based topological descriptors using quadratic, cubic, exponential, and logarithmic regression models. Trial primary completion date: Dec 2023 --> Dec 2024
  • ||||||||||  SCH772984 / Otsuka
    Journal:  Testosterone reduces hippocampal synaptic damage in an androgen receptor-independent manner. (Pubmed Central) -  Nov 22, 2023   
    Meanwhile, Erk1/2 inhibitor SCH772984 blocked the up-regulation of phospho-CREB, PSD95, and GluA1 induced by testosterone in HT22 cells pretreated with flutamide, an androgen antagonist. Collectively, our data indicate that testosterone may ameliorate hippocampal synaptic damage and spatial memory deficit by activating the Erk1/2-CREB signaling pathway in an AR-independent manner.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Pembrolizumab-induced Inflammatory Arthritis: A Case Report () -  Nov 16, 2023 - Abstract #AAPMR2023AAPMR_532;    
    With expanding use of checkpoint inhibitors, more cancer patients are developing RMDs and RMD mimics. It is important for physiatrists to recognize these side effects and refer patients to appropriate specialists.
  • ||||||||||  anastrozole / Generic mfg.
    Journal:  Non-aromatizable androgens modulate the lipopolysaccharide induced expression of the P2X7 receptor in human adipocytes. (Pubmed Central) -  Nov 8, 2023   
    The purinergic system is involved in the inflammatory response of adipocytes, and androgens may modulate its activity. In particular DHT, a non-aromatizable androgen, amplifies the LPS-induced P2X7R gene expression in human adipocytes thus showing a gender regulated response of the expression of this purinergic receptor strongly involved in the inflammatory response in adipose tissue.
  • ||||||||||  anastrozole / Generic mfg.
    Synchronous Breast Cancer and Pheochromocytoma: A Case Series (Hall 2-3) -  Nov 4, 2023 - Abstract #SABCS2023SABCS_1916;    
    She completed treatment for DCIS with lumpectomy and radiation and is currently on adjuvant anastrozole...This series demonstrates the importance of keeping pheochromocytomas in the differential during the workup of adrenal masses prior to surgical interventions. Additionally, they demonstrate how the usual workup and management of breast cancer does not take into account these rare but significant diagnoses, and that can result in fatal consequences.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    A Case of Multifocal Ductal Breast Carcinoma with Extension into Lobules and Concurrent Primary Colon Adenocarcinoma (Hall 2-3) -  Nov 4, 2023 - Abstract #SABCS2023SABCS_1913;    
    Neoadjuvant paclitaxel, carboplatin, and pembrolizumab was initiated but she incurred complications of decompensated liver cirrhosis after the second cycle and treatment was held...She was given 4 cycles of adjuvant cyclophosphamide, adriamycin, pembrolizumab and continued on maintenance pembrolizumab...She is planned to start on adjuvant anastrozole...Lastly, our patient is African American, and multifocal tumors occur with a higher incidence in African Americans (43.4%) and Asian patients (37%) as compared to whites (28.9%). This case of breast cancer highlights treatment challenges in a case of multifocal multicentric breast cancer occurring concurrently with a secondary primary colonic cancer.
  • ||||||||||  anastrozole / Generic mfg.
    Case Series: Invasive Secretory Carcinoma (Hall 2-3) -  Nov 4, 2023 - Abstract #SABCS2023SABCS_1283;    
    She underwent adjuvant whole breast radiation, axillary nodal radiation, and was placed on anastrozole therapy for 5 years...The tumor cells are positive for CK5/6 (patchy), CD117, ER (focal and weakly), and S100; negative for p63 and calponin, supporting the diagnosis of invasive secretory carcinoma. NTRK3 gene rearrangement was detected on fluorescence in situ hybridization (FISH).
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Exceptional long-term disease control on pembrolizumab monotherapy in a patient with TMB-high PMS2-mutated MMR-deficient triple negative breast cancer brain metastasis (Hall 2-3) -  Nov 4, 2023 - Abstract #SABCS2023SABCS_968;    
    She underwent partial mastectomy, axillary dissection, radiation, and received adjuvant anastrozole...She received adjuvant chemotherapy (AC-T) and 1 year of trastuzumab...Two years later, concern for progression from rising tumor markers led to addition of concurrent carboplatin/gemcitabine for 5 cycles...Altogether, this case is a remarkable addition to growing evidence that TMB could be a biomarker for predicting response to ICI therapy and provides an example of ICI efficacy in the setting of BCBM. Further research on additional genomic, clinical, and pathologic features associated with ICI responsiveness is warranted for greater precision in BCBM management.
  • ||||||||||  Real-World Data of Neuroendocrine Neoplasms of Breast (Hall 2-3) -  Nov 4, 2023 - Abstract #SABCS2023SABCS_921;    
    Of these, 79 presented with localized disease, 18 were metastatic at presentation. 88 (91%) were invasive ductal carcinoma (IDC), and 64 (81%) were local disease at presentation and rest were metastatic.
  • ||||||||||  anastrozole / Generic mfg.
    Adipose-enriched peri-tumoral stroma prognosticates poorer survival in breast cancers (Hall 2-3) -  Nov 4, 2023 - Abstract #SABCS2023SABCS_696;    
    P3
    DDFS was superior for patients with higher ER and PgR standardized units compared with those with HSCOREs <-1. Adjunctive statistical standardization, similar to that mandated for clinical practice by the World Health Organization for BMD, should improve inter-laboratory comparability of biomarker results for similar patient populations.
  • ||||||||||  Nerlynx (neratinib) / Puma, Knight Therap, Pierre Fabre
    A rare unilateral expression of hand-foot syndrome: a case report (Hall 2-3) -  Nov 4, 2023 - Abstract #SABCS2023SABCS_658;    
    Preexisting hemiparesis may play a role in protecting against HFS development, suggesting the involvement of mechanical stress. Patients should be advised to avoid activities that subject the palms and soles to excessive friction.
  • ||||||||||  Epidiolex (cannabidiol) / Jazz
    Evaluating Symptom Clusters in Patients with Breast Cancer Experiencing Aromatase Inhibitor-Associated Musculoskeletal Symptoms (Hall 2-3) -  Nov 4, 2023 - Abstract #SABCS2023SABCS_551;    
    P2
    Though it is difficult to extrapolate results from a small population, the unexpected absence of co-occurring symptoms in this population raises additional questions about the interplay of AIMSS and other symptoms commonly reported in interventional AIMSS studies. Follow-up PRO data will be obtained in this clinical trial, allowing us to examine the impact of CBD use on pain, pain interference, and other patient-reported symptoms, as well as to explore which patients are more likely to obtain benefit from CBD treatment.
  • ||||||||||  anastrozole / Generic mfg.
    Impact of Baseline Oestradiol and Testosterone on the Preventive Effect of Anastrozole (Stars at Night Ballroom 3-4) -  Nov 4, 2023 - Abstract #SABCS2023SABCS_359;    
    As aromatase inhibitors effectively eliminate the production of oestradiol in postmenopausal women, these results suggest they may be more effective in postmenopausal women with high oestradiol or testosterone levels, and raise questions about their value in women in the lower quartile of serum levels for these hormones for prevention and possibly adjuvant treatment. Table: Risk of breast cancer by quartiles of the oestradiol/SHBG in ratio high risk women treated with anastrozole or placebo.
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Verzenio (abemaciclib) / Eli Lilly
    CDK4/6 inhibition is a potential vulnerability in NF1-depleted ER+ breast cancer (Hall 1) -  Nov 4, 2023 - Abstract #SABCS2023SABCS_244;    
    These data support a model whereby ER and RAS signaling converge upon CDK4/6, and CDK4/6 activation is a key survival mechanism when ER signaling is attenuated by treatment in NF1-depleted ER+ breast cancer cells. This apparent addiction for CDK4/6 activity makes NF1-depleted ER+ breast tumors vulnerable to CDK4/6 inhibition, thus creating a potential therapeutic opportunity to match CDK4/6 inhibition with patients who can benefit the most.
  • ||||||||||  Orserdu (elacestrant) / Menarini
    Review, Journal, Metastases:  Elacestrant for ER-Positive HER2-Negative Advanced Breast Cancer. (Pubmed Central) -  Oct 27, 2023   
    Phase 1 and 3 trials showed elacestrant was safe and improved progression-free survival in patients with endocrine receptor 1 (ESR1) mutations who failed cyclin-dependent kinase 4/6 inhibitor (CDK 4/6i) plus 1 prior endocrine therapy compared with standard of care (SOC) (fulvestrant, anastrozole, letrozole, or exemestane monotherapy). Elacestrant is currently being studied in CDK 4/6 inhibitor na
  • ||||||||||  Soltamox (tamoxifen citrate) / Jazz, Firmagon (degarelix) / Astellas, Ferring, Verzenio (abemaciclib) / Eli Lilly
    Enrollment open:  ETHAN - ET for Male BC (clinicaltrials.gov) -  Oct 23, 2023   
    P2,  N=60, Recruiting, 
    Elacestrant is currently being studied in CDK 4/6 inhibitor na Not yet recruiting --> Recruiting
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Journal:  Concomitant Use of Proton Pump Inhibitors and Palbociclib Among Patients With Breast Cancer. (Pubmed Central) -  Oct 22, 2023   
    Both clinical PFS and OS in the concomitant PPI group were consistently poor in patients receiving endocrine-sensitive and endocrine-resistant treatment. These findings suggest that concomitant use of PPIs with palbociclib may hinder the complete therapeutic benefits of palbociclib in patients with breast cancer.
  • ||||||||||  Vesanoid (tretinoin) / Roche
    Trial completion date, Trial primary completion date, Combination therapy:  Evaluation of ATRA Activity in Combination With Anastrozole in Pre-operative Phase of Operable Early Breast Cancer (clinicaltrials.gov) -  Oct 19, 2023   
    P2,  N=112, Recruiting, 
    Men with azoospermia rarely respond to anastrozole and should be counseled on alternative treatments. Trial completion date: Sep 2023 --> Sep 2024 | Trial primary completion date: Aug 2023 --> Aug 2024